Pfizer's next play: A vaccine maker and pandemic 'partner' to governments

Dow Jones2021-05-05

The company's COVID-19 vaccine generated $3.4 billion in revenue in the first quarter of 2021

Pfizer Inc.'s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker's top-selling drug and forging a new path into infectious diseases for the legacy drug maker.

Shares of Pfizer $(PFE)$ gained 0.2% in trading on Tuesday after the company announced earnings for the first quarter of 2021. It updated guidance to $26 billion for 2021, up from an earlier forecast for $15 billion.

To put this in perspective, the company's top-selling cholesterol pill Lipitor brought in $13 billion in annual sales at its peak, in 2006, and generated a total of $94 billion over a 15-year span, according to FiercePharma .

Here are a few additional details to pay attention to from Pfizer's first-quarter earnings:

Pfizer's stock is up 8.3% for the year, while the S&P 500 has gained 11.6%.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
3